Skip to main content

HUELLAS MOLECULARES HACIA LA PROGRESION Y LA RESISTENCIA DE LA ENFERMEDAD DE ALZHEIMER

PID2022-143263OB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2022
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Neuroinflammation in Alzheimer disease

  • Heneka, Michael T.
  • Flier, Wiesje M. van der
  • Jessen, Frank
  • Hoozemanns, Jeroen
  • Thal, Dietmar Rudolf
  • Boche, Delphine
  • Brosseron, Frederic
  • Teunissen, Charlotte E.
  • Zetterberg, Henrik
  • Jacobs, Andreas H.
  • Edison, Paul
  • RamÍrez, Alfredo
  • Cruchaga, Carlos
  • Lambert, Jean-Charles
  • Ruíz Laza, Agustín
  • Sánchez-Mut, José Vicente
  • Fischer, Andre
  • Castro, Sergio
  • Stein, Thor D.
  • Kleineidam, Luca
  • Wagner, Michael
  • Neher, Jonas J.
  • Cunningham, Colm
  • Singhrao, Sim K.
  • Prinz, Marco
  • Glass, Christopher K.
  • Schlachetzki, Johannes C. M.
  • Butovsky, Oleg
  • Kleemann, Kilian
  • De Jaeger, Philip L.
  • Scheiblich, Hannah
  • Brown, Guy C.
  • Landreth, Gary
  • Moutinho, Miguel
  • Grutzendler, Jaime
  • Gomez-Nicola, Diego
  • McManus, Róisín M.
  • Andreasson, Katrin
  • Ising, Christina
  • Karabag, Deniz
  • Baker, Darren J.
  • Liddelow, Shane A.
  • Verkhratsky, Alexei
  • Tansey, Malu
  • Monsonego, Alon
  • Aigner, Ludwig
  • Dorothée, Guillaume
  • Nave, Klaus-Armin
  • Simons, Mikael
  • Constantin, Gabriela
  • Rosenzweig, Neta
  • Pascual Bravo, Alberto
  • Petzold, Gabor C.
  • Kipnis, Jonathan
  • Venegas, Carmen
  • Colonna, Marco
  • Walter, Jochen
  • Tenner, Andrea J.
  • O'Banion, M. Kerry
  • Steinert, Joern R.
  • Feinstein, Douglas L.
  • Sastre, Magdalena
  • Bhaskar, Kiran
  • Hong, Soyon
  • Schafer, Dorothy P.
  • Golde, Todd
  • Ransohoff, Richard M.
  • Morgan, David
  • Breitner, John
  • Mancuso, Renzo
  • Riechers, Sean-Patrick
Increasing evidence points to a pivotal role of immune processes in the pathogenesis of Alzheimer disease, which is the most prevalent neurodegenerative and dementia-causing disease of our time. Multiple lines of information provided by experimental, epidemiological, neuropathological and genetic studies suggest a pathological role for innate and adaptive immune activation in this disease. Here, we review the cell types and pathological mechanisms involved in disease development as well as the influence of genetics and lifestyle factors. Given the decade-long preclinical stage of Alzheimer disease, these mechanisms and their interactions are driving forces behind the spread and progression of the disease. The identification of treatment opportunities will require a precise understanding of the cells and mechanisms involved as well as a clear definition of their temporal and topographical nature. We will also discuss new therapeutic strategies for targeting neuroinflammation, which are now entering the clinic and showing promise for patients., A.F. received funds from Germany’s Excellence Strategy (EXC 2067/1 390729940). A.J.T. is supported by the National Institutes of Health (NIH) grant (U54 AG054349). D.L.F. is supported by grant IK6BX004852-01 from the Department of Veterans Affairs. D.B. acknowledges support from the Medical Research Council UK, Alzheimer’s Research UK and the European Union. She thanks the UK Brain Banks and BRAIN UK for providing tissue for her studies. D.J.B. is supported by the NIH (R01AG053229, R01AG068076, U54AG079779), the Minnesota Partnership for Biotechnology and Medical Genomics (MNP #18.04), and the Glenn Foundation for Medical Research. C.Cunningham is funded by the Irish Research Council, National Institutes of Health, the Dutch Research Council (ZonMW) and Alzheimer’s Research UK. D.G.-N. was supported by grants from the Medical Research Council (MR/P024572/1, MR/Y004116/1). C.V. was supported by the RYC2022-036191-I, funded by MCIN/AEI/10.13039/501100011033 and European Social Fund Plus. C.T. is supported by the European Commission Marie Curie International Training Network, grant agreement No. 860197 (MIRIADE) and TAME, Innovative Medicines Initiatives 3TR (Horizon 2020, grant No. 831434), EPND (IMI 2 Joint Undertaking (JU), grant No. 101034344) and JPND (bPRIDE, CCAD), European Partnership on Metrology, co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States (22HLT07 NEuroBioStand), CANTATE project funded by the Alzheimer Drug Discovery Foundation, Alzheimer Association, Michael J Fox Foundation, Health Holland, ZonMW, Alzheimer Drug Discovery Foundation, The Selfridges Group Foundation, and Alzheimer Netherlands. C.T. is a recipient of ABOARD, which is a public–private partnership receiving funding from ZonMW (#73305095007) and Health Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). C.T. is a recipient of TAP-dementia, a ZonMw-funded project (#10510032120003) in the context of the Dutch National Dementia Strategy. D.M. is supported by ZEN24-1070221 from the Alzheimer’s Association and R01 AG055072, R01 AG077651, and P30 AG072931 from NIH. D.R.T. received support from Research Foundation – Flanders (FWO; G065721N), Stichting Alzheimer Onderzoek (SAO/FRA 2023/0009) and Alzheimer’s Association (22-AAIIA-963171). D.S. was supported by NINDS-R01NS117533, NIA-RF1AG068281 and NIH-R24OD036199. G.C. is supported by the NextGenerationEU and National Recovery and Resilience Plan, National Biodiversity Future Center and PE grant MNESYS (PE0000006). G.C.P. received funding from the German Science Foundation (PE1193/6-2), ERA-NET (MICRO-BLEEDs and TACKLE-CSVD), and the Fondation Leducq (Transatlantic Network of Excellence 23CVD03); he is a member of the Deutsche Forschungsgemeinschaft (DFG; German Research Foundation) excellence cluster ImmunoSensation2. G.D. thanks the Agence Nationale de la Recherche (grants #ANR-21-CE17-0054-01; #ANR-24-CE18-2770-02), Fondation Alzheimer, Fondation pour la Recherche Médicale, Fondation Pierre Deniker, Association France Alzheimer and Fondation Vaincre Alzheimer for funding his research. H.Z. is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union’s Horizon Europe Research and Innovation Programme under grant agreement No. 101053962, and Swedish State Support for Clinical Research (#ALFGBG-71320). J.B. was supported by a research grant from the Canada Institute for Health Research. J.G. was funded by the JPB Foundation, the Cure Alzheimers Fund and The Alzheimer’s Association. J.C.M.S. is supported by a clinical fellowship from the Alzheimer’s Association (AACSF). J.V.S.-M. is supported by grants from the Pasqual Maragall Foundation (PMRP/2022/1184) and Spanish (PID2022-143263OB-I00) and Valencian (PROMETEO/2021/045) governments. K.-A.N. has been supported by grants from the DFG (TRR274), European Research Council (ERC; AdG MyeliNANO) and the Adelson Medical Research Foundation (AMRF). K.B. was funded by the NIH grant RF1NS083704. L.A. is supppoted by the Austrian Science Fund FWF Project #P35417-B. K.A. is the Edward F. and Irene Thiele Pimley Professor of Neurology and Neurological Sciences and is supported by NIH grants RF1 AG070839, RF1 AG079131, and RF1 AG080742, the Wu Tsai Neurosciences Institute Knight Initiative for Brain Resilience at Stanford University, and she is a Chan Zuckerberg Biohub-San Francisco Investigator. M.K.O. is supported by grant 80NSSC21K0542 from NASA. O.B. is funded by grants from NIH-STTR (R41AG073059), Cure Alzheimer Fund, BrightFocus Foundation (2020A016806), NIH/NIA (R01 AG051812), NIH (R01 AG054672), NIH (R01 AG075509), NIH (R01 NS088137-10), NIH (R21AG076982), and NIH/NINDS (R01 NS088137). R.Mancuso has funding from the ERC under the European Union’s Horizon 2020 Research and Innovation Programme (project no. 101041867 - XenoMicrogliaAD), Fonds voor Wetenschappelijk Onderzoek (grants No. G0C9219N, G056022N and G0K9422N), the Alzheimer’s Association USA (2018-AARF-591110, 2018-AARF-591110-RAPID, E2A-23-1148152, ABA-22-968700). He also receives funding from BrightFocus Foundation (A2021034S), SAO-FRA (grants No. 2021/0021 and SAO-FRA 20230019) and the University of Antwerp (BOF-TOP 2022-2025). R.McManus is supported by grants from the European Union Joint Programme Neurodegenerative Disease (JPND) (01ED2409B), the Alzheimer’s Association (24AARF-1243474) and from the DFG, under Germany’s Excellence Strategy – EXC2151 – 390873048, along with Project-ID 432325352 – SFB 1454. S.C.G. is supported by the Alzheimer Forschung Initiative e.V (Grant 21060), the Hertie Network of Excellence in Clinical Neuroscience (Grant 2021-1A-12), the Bonn Neuroscience Clinician Scientist Program (Neuro-aCSis), and the DFG (EXC2151–390873048). S.H. is supported by the UK Dementia Research Institute (UKDRI-1011) and the Chan Zuckerberg Initiative Neurodegeneration Network. J.J.N. is currently supported through Germany’s Excellence Strategy (EXC 2145 SyNergy– ID 390857198), the Else Kröner-Fresenius Stiftung (2018-A158), the Charitable Hertie Foundation (P1200024), the BrightFocus Foundation (A2021035S) and Alzheimer’s Association (ADSF-24-1345513-C). W.M.vdF. performs research at the Alzheimer Center Amsterdam as part of the neurodegeneration research programme of Amsterdam Neuroscience. Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting Steun Alzheimercentrum Amsterdam. The chair held by W.M.vdF. is supported by the Pasman Stichting. W.M.vdF. is a recipient of ABOARD, which is a public–private partnership receiving funding from ZonMW (#73305095007) and Health Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). W.M.vdF. is a recipient of TAP-dementia (www.tap-dementia.nl), receiving funding from ZonMw (#10510032120003)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Sex-dependent interferon signaling contributes to female-biased vulnerability in Alzheimer’s disease

  • López-López, Verónica
  • Iniesta, Gerard
  • Galán-Ganga, Marcos
  • Expósito-Coca, Alejandro
  • Durán-Laforet, Violeta
  • Bhojwani-Cabrera, Aysha M.
  • Navarrón, Carmen M.
  • Guillot-Fernández, Marina
  • Venero, José L.
  • Sánchez-Mut, José V.
  • Barco, Ángel
  • Giralt, Albert
  • López-Atalaya, José P.
[Data availability] The transcriptomics data sets generated in this study can be accessed at the GEO public repository using the accession number GSE304521 and GSE304362. In addition, publicly available single-cell RNA-seq data (GSE173242) were also reanalyzed as part of this study [46]. Human RNA-seq data used in this study were obtained from the publicly available The Mount Sinai Brain Bank (MSBB) study, hosted on the AD Knowledge Portal (https://adknowledgeportal.org/). The dataset is accessible via Synapse (https://www.synapse.org/): syn3159438; metadata: syn29855570; count data: syn27068754). The results published here are in whole or in part based on data obtained from the AD Knowledge Portal (https://adknowledgeportal.org/). These data were generated from postmortem brain tissue collected through the Mount Sinai VA Medical Center Brain Bank and were provided by Dr. Eric Schadt from Mount Sinai School of Medicine. Processed data and code used for statistical analysis, gene expression processing, and Fig. generation are available upon request from the corresponding author., Alzheimer’s disease (AD) disproportionately affects women, yet the biological basis of this sex bias remains unclear. Here, we identify sex-dependent interferon signaling as a contributor to this disparity. Transcriptomic profiling of postmortem AD tissue and APP/PS1 mice revealed preferential enrichment of interferon-responsive gene programs in females. In APP/PS1 mice, heightened interferon responses were associated with increased neurodegenerative features, and single-cell transcriptomic analyses identified microglia as a major cellular compartment engaging interferon responses. To test causality, we manipulated interferon signaling in vivo. Acute systemic interferon activation promoted AD-like neuropathological alterations. Genetic amplification of interferon signaling in microglia exacerbated neuroinflammatory and neurodegenerative features in APP/PS1 mice, whereas pharmacological inhibition through cGAS-STING blockade suppressed interferon responses, reduced neuropathology, and preserved cognitive performance in female APP/PS1 mice. Together, these findings identify microglial interferon signaling as a modifiable contributor to AD-associated neuropathology and suggest a neuroimmune mechanism underlying the increased vulnerability of females to the disease., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. V.L-L. is the recipient of a 2021 neuroscience doctoral fellowship from the Fundación Tatiana Pérez de Guzmán el Bueno. G.I. holds a Formación de Personal Investigador (FPI) contract (CEX2021-001165-S-20–2), associated with “Severo Ochoa” grant CEX2021-001165-S from the MCIU/AEI/https://doi.org/10.13039/501100011033. M.G.-G received the support from “la Caixa” Foundation (ID 100010434), fellowship code is LCF/BQ/DR21/11880016. V.D-L holds a CIAPOS contract (CIAPOS/2024/131) funded by Generalitat Valenciana (GVA) and the European Social Fund Plus (ESF +). A.B-C. held a Formación de Personal Investigador (FPI) contract (PRE2019-090492), associated with grant RTI2018-102260-B-I00 awarded to J.P.L-A., and funded by MCIU/AEI/https://doi.org/10.13039/501100011033 and by “ERDF A way of making Europe”. M.G-F. is the recipient of a Formación de Profesorado Universitario contract (FPU22/01375) funded by the Spanish Ministry of Science, Innovation and Universities (MICIU). J.L.V research is supported by grant PID2024-157400OB-I00 funded by MICIU/AEI/https://doi.org/10.13039/501100011033 and ERDF/EU. J.V.S.-M. research is supported by the Pasqual Maragall Foundation (PMRP/2022/1184), the MICIU/AEI/https://doi.org/10.13039/501100011033 and ERDF/EU (PID2022-143263OB-I00), and the Valencian Regional Government’s Prometeo Programme (PROMETEO/2021/045). A.B. research is supported by grants FCAIXA HR22-00394 from Fundación LaCaixa, PID2023-148442NB-I00 from AEI co-financed by ERDF, and CIPROM/2023/15 from the Generalitat Valenciana. A.G. research is supported by European Union NextGenerationEU/PRTR CNS2022—135391 (“Consolidación” program) and the Fundación Ramón Areces (CIVP21A7024). J.P.L-A. research is supported by MCIU/AEI/https://doi.org/10.13039/501100011033 and by ERDF, EU (PID2021-129053OB-I00; PID2024-163108OB-I00), and the Generalitat Valenciana, Conselleria d’Educació, Universitats i Ocupació (PROMETEO 2020/007; CIPROM/2023/15). The Institute of Neurosciences is a Severo Ochoa Center of Excellence (grant CEX2021-001165-S, funded by MCIU/AEI/https://doi.org/10.13039/501100011033)., With funding form the Spanish government through the "Severa Ochoa Centre of Excellence" accreditation (CEX2021-001165-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The PM20D1-OLE pathway induces microglia rewiring to ameliorate Alzheimer disease

  • Pozzi, Victoria
  • Giner de Gracia, Aida
  • Glauser, Liliane
  • Romani, Mario
  • Gunter-Rahman, Fatima
  • González, Alejandro
  • Haj-Yahya, Mahmood
  • Kolla, Rajasekhar
  • Burns, Allison M.
  • Lashuel, Hilal A.
  • Auwerx, Johan
  • Gräff, Johannes
  • Sánchez-Mut, José Vicente
The raw data generated in this study is available in the Gene Expression Omnibus repository (GSE214352) and the analysis code upon request., There is increasing evidence of microglia participation in Alzheimer's disease (AD), which incentives their modulation to intercept the disease. Here, we describe a new mechanism by which the recently AD-associated Peptidase M20 Domain Containing 1 (PM20D1) instructs microglia to tackle AD. We show that the PM20D1-derived N-oleoyl-Leucine (OLE) improves AD pathologies in two animal models of AD. OLE induces microglia association with amyloid beta (Aβ) plaques, reduce their size, number and toxicity, and leads to enhanced neuroprotection and cognition. Furthermore, OLE also increases Aβ chemotaxis and clearance in microglia cultures and enhances cell viability in neurons subjected to AD-related stressors. Finally, we also find evidence for a PM20D1- and OLE-mediated microglia association with amyloid plaques and neuroprotection in human AD brains. In sum, our results provide further insight into the protective role of PM20D1 in AD and support the use of OLE as a microglia-modifying treatment for AD., The work in the laboratory of JVS-M is supported by the SYNAPSIS Foundation-Dementia Research Switzerland ARS, the Pasqual Maragall Foundation under the Pasqual Maragall Researchers Programme (PMRP) (Grant Agreement No 2022-1184), the MICIU/AEI/10.13039/501100011033 and ERDF/EU (PID2022-143263OB-I00), the Severo Ochoa Center of Excellence grant to IN (CEX2021-001165-S), the Valencian Regional Government’s Prometeo Program (PROMETEO/2021/045), and the CSIC Interdisciplinary Thematic Platform (PTI + ) NEURO-AGINGl+ (PTI-NEURO-AGING + ). Funding for this work in the laboratory of JG was provided by the Swiss National Science Foundation (31003A_182656) and by a JPND collaborative research grant (31ND30_179601). The work in the laboratory of JA was supported by grants the Ecole Polytechnique Fédérale de Lausanne (EPFL), the European Research Council (ERC-AdG-787702), the Swiss National Science Foundation (SNSF 31003A_179435), and the GRL grant of the National Research Foundation of Korea (NRF 2017K1A1A2013124). VP-R (PRE2020-093825) and AG-R (PRE2020-093389) are supported by MICIU/AEI /10.13039/501100011033 and “ESF Investing in your future”. AGG was supported by the SYNAPSIS Foundation-Dementia Research Switzerland ARS. FG-R was supported by a ThinkSwiss and EPFL scholarship., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001165-S), Peer reviewed, Modelo experimental animal, Mamíferos - Roedores, in vitro